Wikipedia

Aging-associated diseases

An aging-associated disease (commonly termed age-related disease, ARD) is a disease that is most often seen with increasing frequency with increasing senescence. They are essentially complications of senescence, distinguished from the aging process itself because all adult animals age (with rare exceptions) but not all adult animals experience all age-associated diseases. The term does not refer to age-specific diseases, such as the childhood diseases chicken pox and measles, only diseases of the elderly. They are also not accelerated aging diseases, all of which are genetic disorders.

Age-specific SEER incidence rates, 2003–2007

Examples of aging-associated diseases are atherosclerosis and cardiovascular disease, cancer, arthritis, cataracts, osteoporosis, type 2 diabetes, hypertension and Alzheimer's disease. The incidence of all of these diseases increases exponentially with age.[1]

Of the roughly 150,000 people who die each day across the globe, about two thirds—100,000 per day—die of age-related causes.[2] In industrialized nations, the proportion is higher, reaching 90%.[2]

Patterns of differences

edit

By age 3, about 30% of rats have had cancer, whereas by age 85 about 30% of humans have had cancer. Humans, dogs and rabbits get Alzheimer's disease, but rodents do not. Elderly rodents typically die of cancer or kidney disease, but not of cardiovascular disease. In humans, the relative incidence of cancer increases exponentially with age for most cancers, but levels off or may even decline by age 60–75[3](although colon/rectal cancer continues to increase).[4]

People with the so-called segmental progerias are vulnerable to different sets of diseases. Those with Werner's syndrome experience osteoporosis, cataracts, and, cardiovascular disease, but not neurodegeneration or Alzheimer's disease; those with Down syndrome have type 2 diabetes and Alzheimer's disease, but not high blood pressure, osteoporosis or cataracts. In Bloom syndrome, those affected most often die of cancer.

Research

edit

Aging (senescence) increases vulnerability to age-associated diseases, whereas genetics determines vulnerability or resistance between species and individuals within species. Some age-related changes (like graying hair) are said to be unrelated to an increase in mortality. But some biogerontologists believe that the same underlying changes that cause graying hair also increase mortality in other organ systems and that understanding the incidence of age-associated disease will advance knowledge of the biology of senescence just as knowledge of childhood diseases advanced knowledge of human development.[5]

Strategies for engineered negligible senescence (SENS) is an emerging research strategy that aims to repair "root causes" for age-related illness and degeneration, as well as develop medical procedures to periodically repair all such damage in the human body, thereby maintaining a youth-like state indefinitely.[6] The SENS programme has identified seven types of aging-related damage, and feasible solutions have been outlined for each. Some critics argue that the SENS agenda is optimistic at best, and that the aging process is too complex and little-understood for SENS to be scientific or implementable in the foreseeable future.[7][8][9] It has been proposed that age-related diseases are mediated by vicious cycles.[10]

On the basis of extensive research, DNA damage has emerged a major culprit in cancer and numerous other diseases related to ageing.[11] DNA damage can initiate the development of cancer or other aging related diseases depending on several factors. These include the type, amount, and location of the DNA damage in the body, the type of cell experiencing the damage and its stage in the cell cycle, and the specific DNA repair processes available to react to the damage.[11]

Types

edit

Macular degeneration

edit

Age-related macular degeneration (AMD) is a disease that affects the eyes and can lead to vision loss through break down of the central part of the retina called the macula. Degeneration can occur in one eye or both and can be classified as either wet (neovascular) or dry (atrophic). Wet AMD commonly is caused by blood vessels near the retina that lead to swelling of the macula.[12] The cause of dry AMD is less clear, but it is thought to be partly caused by breakdown of light-sensitive cells and tissue surrounding the macula. A major risk factor for AMD is age over the age of 60.[13]

Alzheimer's

edit

Alzheimer's disease is classified as a "protein misfolding" disease. Aging causes mutations in protein folding, and as a result causes deposits of abnormal modified proteins to accumulate in specific areas of the brain. In Alzheimer's, deposits of Beta-amyloid and hyperphosphorylated tau protein form extracellular plaques and extracellular tangles.[14] These deposits are shown to be neurotoxic and cause cognitive impairment due to their initiation of destructive biochemical pathways.[15]

Atherosclerosis

edit

Atherosclerosis is categorized as an aging disease and is brought about by vascular remodeling, the accumulation of plaque, and the loss of arterial elasticity. Over time, these processes can stiffen the vasculature. For these reasons, older age is listed as a major risk factor for atherosclerosis.[16] Specifically, the risk of atherosclerosis increases for men above 45 years of age and women above 55 years of age.[17]

Benign prostatic hyperplasia

edit

Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate gland due to increased growth.[18] An enlarged prostate can result in incomplete or complete blockage of the bladder and interferes with a man's ability to urinate properly. Symptoms include overactive bladder, decreased stream of urine, hesitancy urinating, and incomplete emptying of the bladder.[19][20] By age 40, 10% of men will have signs of BPH and by age 60, this percentage increases by 5 fold. Men over the age of 80 have over a 90% chance of developing BPH and almost 80% of men will develop BPH in their lifetime.[18][21]

Cancer

edit

Although it is possible for cancer to strike at any age, most patients with invasive cancer are over 65,[22] and the most significant risk factor for developing cancer is age.[22] According to cancer researcher Robert A. Weinberg, "If we lived long enough, sooner or later we all would get cancer."[23] Some of the association between aging and cancer is attributed to immunosenescence,[24] errors accumulated in DNA over a lifetime[25] and age-related changes in the endocrine system.[26] Aging's effect on cancer is complicated by factors such as DNA damage and inflammation promoting it and factors such as vascular aging and endocrine changes inhibiting it.[27]

Parkinson's

edit

Parkinson's disease, or simply Parkinson's,[28] is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. The disease has many complications, including Dementia, depression, anxiety.[29] Parkinson's disease typically occurs in people over the age of 60, of whom about one percent are affected.[30][31] The prevalence of Parkinson's disease dementia also increases with age, and to a lesser degree, duration of the disease.[32] Exercise in middle age may reduce the risk of PD later in life.[33]

Stroke

edit

Stroke was the second most frequent cause of death worldwide in 2011, accounting for 6.2 million deaths (~11% of the total).[34] Stroke could occur at any age, including in childhood, the risk of stroke increases exponentially from 30 years of age, and the cause varies by age.[35] Advanced age is one of the most significant stroke risk factors. 95% of strokes occur in people age 45 and older, and two-thirds of strokes occur in those over the age of 65.[36][37] A person's risk of dying if he or she does have a stroke also increases with age.

Endocrine diseases

edit

Studies in animal models show that clearance of senescent cells improves multiple age related endocrine disorders.[38]

Osteoporosis

edit

Bone density declines with age. By the age of 85 years, ~70% of women and 30% of men have a osteoporosis defined as a bone density less than or equal to 2.5 standard deviations lower than young adults.[39]

Metabolic syndrome

edit

The metabolic syndrome is the co-occurrence of metabolic risk factors for type 2 diabetes and cardiovascular disease (abdominal obesity, hyperglycemia, dyslipidemia, and hypertension). The prevalence of the metabolic syndrome increases with age reaching close to 50% of people over 60 years old in the USA.[40] as

See also

edit

References

edit
  1. ^ Belikov AV (January 2019). "Age-related diseases as vicious cycles". Ageing Research Reviews. 49: 11–26. doi:10.1016/j.arr.2018.11.002. PMID 30458244. S2CID 53567141.
  2. ^ a b de Grey A (2007). "Life Span Extension Research and Public Debate: Societal Considerations" (PDF). Studies in Ethics, Law, and Technology. 1 (1, Article 5). CiteSeerX 10.1.1.395.745. doi:10.2202/1941-6008.1011. S2CID 201101995. Archived from the original (PDF) on October 13, 2016. Retrieved August 7, 2011.
  3. ^ Belikov AV (September 2017). "The number of key carcinogenic events can be predicted from cancer incidence". Scientific Reports. 7 (1): 12170. Bibcode:2017NatSR...712170B. doi:10.1038/s41598-017-12448-7. PMC 5610194. PMID 28939880.
  4. ^ "SEER Cancer Statistics Review, 1975–2003" (PDF). Surveillance Epidemiology and End Results (SEER). National Cancer Institute. Archived from the original (PDF) on 2006-09-25. Retrieved 2006-11-20.
  5. ^ Hayflick L (June 2004). "The not-so-close relationship between biological aging and age-associated pathologies in humans". The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 59 (6): B547–B550. doi:10.1093/gerona/59.6.B547. PMID 15215261.
  6. ^ "The SENS Platform: An Engineering Approach to Curing Aging Archived 2008-08-31 at the Wayback Machine". Methuselah Foundation. Retrieved on June 28, 2008.
  7. ^ Warner H, Anderson J, Austad S, Bergamini E, Bredesen D, Butler R, et al. (November 2005). "Science fact and the SENS agenda. What can we reasonably expect from ageing research?". EMBO Reports. 6 (11): 1006–1008. doi:10.1038/sj.embor.7400555. PMC 1371037. PMID 16264422.
  8. ^ de Grey AD (November 2005). "Like it or not, life-extension research extends beyond biogerontology". EMBO Reports. 6 (11): 1000. doi:10.1038/sj.embor.7400565. PMC 1371043. PMID 16264420.
  9. ^ de Grey, Aubrey. "The biogerontology research community's evolving view of SENS Archived 2008-10-20 at the Wayback Machine". Methuselah Foundation. Retrieved on July 1, 2008.
  10. ^ Belikov AV (January 2019). "Age-related diseases as vicious cycles". Ageing Research Reviews. 49: 11–26. doi:10.1016/j.arr.2018.11.002. PMID 30458244. S2CID 53567141.
  11. ^ a b Hoeijmakers JH (October 2009). "DNA damage, aging, and cancer". The New England Journal of Medicine. 361 (15): 1475–1485. doi:10.1056/NEJMra0804615. PMID 19812404.
  12. ^ Zarbin MA (April 2004). "Current concepts in the pathogenesis of age-related macular degeneration". Archives of Ophthalmology. 122 (4): 598–614. doi:10.1001/archopht.122.4.598. PMID 15078679.
  13. ^ "Facts About Age-Related Macular Degeneration | National Eye Institute". nei.nih.gov. Archived from the original on 2015-12-22. Retrieved 2019-08-06.
  14. ^ Franceschi C, Garagnani P, Morsiani C, Conte M, Santoro A, Grignolio A, et al. (2018-03-12). "The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates". Frontiers in Medicine. 5: 61. doi:10.3389/fmed.2018.00061. PMC 5890129. PMID 29662881.
  15. ^ Bloom GS (April 2014). "Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis". JAMA Neurology. 71 (4): 505–508. doi:10.1001/jamaneurol.2013.5847. PMID 24493463.
  16. ^ Wang JC, Bennett M (July 2012). "Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence". Circulation Research. 111 (2): 245–259. doi:10.1161/CIRCRESAHA.111.261388. PMID 22773427.
  17. ^ "Atherosclerosis | National Heart, Lung, and Blood Institute (NHLBI)". www.nhlbi.nih.gov. Archived from the original on 2017-10-05. Retrieved 2019-08-05.
  18. ^ a b "Prostate Enlargement (Benign Prostatic Hyperplasia) | NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases. Archived from the original on 2017-10-04. Retrieved 2019-08-06.
  19. ^ "What is Benign Prostatic Hyperplasia (BPH)? – Urology Care Foundation". www.urologyhealth.org. Archived from the original on 2019-08-06. Retrieved 2019-08-06.
  20. ^ "Benign Prostatic Hyperplasia (BPH) Guideline – American Urological Association". www.auanet.org. Archived from the original on 2021-04-20. Retrieved 2019-08-06.
  21. ^ "Medical Student Curriculum: Benign Prostatic Hypertrophy (BPH) – American Urological Association". www.auanet.org. Archived from the original on 2019-05-15. Retrieved 2019-08-06.
  22. ^ a b Coleman WB, Rubinas TC (2009). "4". In Tsongalis GJ, Coleman WL (eds.). Molecular Pathology: The Molecular Basis of Human Disease. Amsterdam: Elsevier Academic Press. p. 66. ISBN 978-0-12-374419-7.
  23. ^ Johnson G (28 December 2010). "Unearthing Prehistoric Tumors, and Debate". The New York Times. Archived from the original on 24 June 2017.
  24. ^ Pawelec G, Derhovanessian E, Larbi A (August 2010). "Immunosenescence and cancer". Critical Reviews in Oncology/Hematology. 75 (2): 165–172. doi:10.1016/j.critrevonc.2010.06.012. PMID 20656212.
  25. ^ Alberts B, Johnson A, Lewis J, et al. (2002). "The Preventable Causes of Cancer". Molecular biology of the cell (4th ed.). New York: Garland Science. ISBN 978-0-8153-4072-0. Archived from the original on 2 January 2016. A certain irreducible background incidence of cancer is to be expected regardless of circumstances: mutations can never be absolutely avoided, because they are an inescapable consequence of fundamental limitations on the accuracy of DNA replication, as discussed in Chapter 5. If a human could live long enough, it is inevitable that at least one of his or her cells would eventually accumulate a set of mutations sufficient for cancer to develop.
  26. ^ Anisimov VN, Sikora E, Pawelec G (August 2009). "Relationships between cancer and aging: a multilevel approach". Biogerontology. 10 (4): 323–338. doi:10.1007/s10522-008-9209-8. PMID 19156531. S2CID 17412298.
  27. ^ de Magalhães JP (May 2013). "How ageing processes influence cancer". Nature Reviews. Cancer. 13 (5): 357–365. doi:10.1038/nrc3497. PMID 23612461. S2CID 5726826.
  28. ^ "Understanding Parkinson's". Parkinson's Foundation. Archived from the original on 12 August 2020. Retrieved 12 August 2020.
  29. ^ Sveinbjornsdottir S (October 2016). "The clinical symptoms of Parkinson's disease". Journal of Neurochemistry. 139 (Suppl 1): 318–324. doi:10.1111/jnc.13691. PMID 27401947.
  30. ^ "Parkinson's Disease Information Page". NINDS. 30 June 2016. Archived from the original on 4 January 2017. Retrieved 18 July 2016.
  31. ^ Carroll WM (2016). International Neurology. John Wiley & Sons. p. 188. ISBN 978-1118777367. Archived from the original on 8 September 2017.
  32. ^ Garcia-Ptacek S, Kramberger MG (September 2016). "Parkinson Disease and Dementia". Journal of Geriatric Psychiatry and Neurology. 29 (5): 261–270. doi:10.1177/0891988716654985. PMID 27502301. S2CID 21279235.
  33. ^ Ahlskog JE (July 2011). "Does vigorous exercise have a neuroprotective effect in Parkinson disease?". Neurology. 77 (3): 288–294. doi:10.1212/wnl.0b013e318225ab66. PMC 3136051. PMID 21768599.
  34. ^ "The top 10 causes of death". WHO. Archived from the original on 2013-12-02.
  35. ^ Ellekjaer H, Holmen J, Indredavik B, Terent A (November 1997). "Epidemiology of stroke in Innherred, Norway, 1994 to 1996. Incidence and 30-day case-fatality rate". Stroke. 28 (11): 2180–2184. doi:10.1161/01.STR.28.11.2180. PMID 9368561. Archived from the original on February 28, 2008.
  36. ^ National Institute of Neurological Disorders and Stroke (NINDS) (1999). "Stroke: Hope Through Research". National Institutes of Health. Archived from the original on 2015-10-04.
  37. ^ Senelick RC, Rossi PW, Dougherty K (1994). Living with Stroke: A Guide for Families. Contemporary Books, Chicago. ISBN 978-0-8092-2607-8. OCLC 40856888.
  38. ^ Stokar J (May 2023). "Targeting senescent cells in ageing-related endocrine diseases". Nature Reviews. Endocrinology. 19 (7): 382. doi:10.1038/s41574-023-00848-x. PMID 37173439. S2CID 258663551.
  39. ^ Trajanoska K, Schoufour JD, de Jonge EA, Kieboom BC, Mulder M, Stricker BH, et al. (September 2018). "Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: The Rotterdam Study". Bone. 114: 116–124. doi:10.1016/j.bone.2018.06.004. PMID 29885926. S2CID 47016339.
  40. ^ Hirode G, Wong RJ (June 2020). "Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016". JAMA. 323 (24): 2526–2528. doi:10.1001/jama.2020.4501. PMC 7312413. PMID 32573660.
edit
 
Wikimedia Commons has media related to Aging-associated diseases.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Aging-associated_diseases&oldid=1251445928"